Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Pfizer

Someone with a lot of money to spend has taken a bullish stance on Pfizer (NYSE:PFE). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Only a quarter of Irish children got Covid-19 vaccine as HSE gives away 300k doses

Poor uptake in this age group is now likely to significantly add to the stress expected in the health sector over the coming winter months as services struggle to cope with a ‘twindemic’ of flu and Covid

Irish Mirror

Check Out What Whales Are Doing With PFE

A whale with a lot of money to spend has taken a noticeably bearish stance on Pfizer. Looking at options history for Pfizer (NYSE:PFE) we detected 20 strange trades.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Anger as Pfizer reveals Covid shots will cost up to $130 when US government pulls free programme

Pfizer insists most Americans will still be able to access free vaccines, but public health advocates accuse it of “shameless” profiteering

The Independent UK

3 Recession-Proof Stocks to Buy in October

Various headwinds, including the widespread fears of a recession, have kept the market clenched in a bear grip. Amid this backdrop, resilient stocks Pfizer (PFE), Waste Management (WM), and Ingles Markets (IMKTA), which belong to essential sectors and possess inelastic demand for their products or services, could be appropriate additions…

StockNews.com

Pfizer says COVID-19 vaccine will cost $110-$130 per dose

Pfizer will charge $110 to $130 for a dose of its COVID-19 vaccine once the U.S. government stops buying the shots

The Independent UK

Pfizer will start charging $110-$130 a dose for COVID vaccines next year

Price increases, while expected, could lead to higher insurance premiums.

Axios

Read news from The Economist, FT, and more,
with one subscription

Did Pfizer make a 'scandalous' admission to the European Parliament about its COVID-19 vaccine?

Despite a claim that has gone viral, Pfizer never said that pre-market trials of its COVID-19 vaccine tested for its effect on transmission of the virus.

ABC News

4 Income Stocks You Could Buy and Hold Forever

As the central banks worldwide are determined to battle sky-high inflation with big rate hikes, top economists warn of a global recession on the way. While volatility is rife in the stock market, reliable dividend-paying stocks Pfizer (PFE), McKesson (MCK), Nutrien (NTR), and Genie Energy (GNE) might be ideal investments…

StockNews.com

At-risk populations in the dark about Covid treatments

Years of sometimes confusing messaging on Covid has left half the people eligible for antiviral treatment unaware of it

Newsroom.co.nz

US clears Novavax COVID booster dose

The Food and Drug Administration has authorized a booster dose of the COVID-19 vaccine made by Novavax

The Independent UK

Covid winter boosters, new vaccines and why side effects may be different

Everybody over 50 is invited for a winter coronavirus jab but not everybody will get the new dual/bivalent vaccines that target multiple strains

Chronicle Live

Ask the Doctors: Omicron variant COVID-19 boosters are now recommended for all

More than 90% of new COVID9 cases nationwide are being caused by infection with the omicron variant. So it’s a relief that there’s a tool to fight that.

Chicago Sun-Times

2 Stocks to Buy Now That Won’t Put Your Portfolio at Risk

With inflation showing no sign of cooling down, the Fed is expected to continue with its rate hikes, raising the chances of a recession. Healthcare stocks have historically provided a cushion in such hazy times. Hence, fundamentally robust stocks Johnson & Johnson (JNJ) and Pfizer (PFE) might be safe additions…

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Looking At Pfizer's Recent Whale Trades

Someone with a lot of money to spend has taken a bearish stance on Pfizer (NYSE:PFE). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Evening Standard

Cancer vaccine being hailed by leading Covid scientists

The husband-and-wife duo who founded BioNTech has made a ‘breakthrough’ in the development of a cancer vaccine

Daily Record

Cancer vaccine could be available by 2030 thanks to scientists behind Covid jab

The professors said that there was 'a number of breakthroughs' during the Covid vaccine development.

Irish Mirror

'Cancer vaccine' could be available in next 10 years as scientists behind vital jab raise hopes

German couple Professors Ugur Sahin and Ozlem Tureci said they are hesitant to say they can find a cure for cancer, but that they have had “breakthroughs” they will keep working on.

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

Vaccines to treat cancer possible by 2030, say BioNTech founders

Uğur Şahin and Özlem Türeci say mRNA Covid vaccine technology could be repurposed to help destroy cancer cells

ABC News

What vaccine can you get, based on your age? These are the recommended COVID-19 vaccines for each age group

More than 14.2 million Australians over the age of 16 have now received three or more doses. So which are the best vaccines for each age group?

The Independent UK

Cancer vaccine could be available by 2030, say scientists behind Covid jab

German couple Professors Ugur Sahin and Ozlem Tureci said they have had ‘breakthroughs’ they will keep working on.

The Denver Post

Colorado’s omicron booster shot campaign picking up after slow start

DENVER — Uptake of new boosters targeting variants of omicron is slowly increasing, in a change from the days when getting a COVID-19 vaccine appointment felt like a competitive sport.

Tribune News Service

Pfizer says booster lifts antibodies for omicron variants

Pfizer Inc. and its German vaccine partner said their booster tailored to the latest omicron variants raised more antibodies against the dominant strains of COVID-19 when compared with the original shot designed to fight the form of the virus.

Asharq Al-Awsat

Pfizer, BioNTech Find Updated COVID Booster Protects against Omicron in Trial

Pfizer and its German partner BioNTech said their COVID-19 vaccine booster, adapted for the BA.4 and the BA.5 subvariants of Omicron, generated a strong immune response and was well-tolerated in testing on humans. With the results, which the companies described as consistent with preclinical data, the partners are following up…

Benzinga

Moderna Rallies On Merck Collaboration: Can Drugmaker Replace COVID Vaccine Revenue?

In late 2020, when the world was searching for a vaccine or cure for COVID-19, the price action in Moderna Inc (NASDAQ: MRNA) was discussed frequently on Benzinga's PreMarket Prep show.

1 … 34 35 36 37

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

UK Health Security Agency

Food and Drug Administration

336 stories

Pfizer Inc

312 stories

British Heart Foundation

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.